New drug cocktail shows promise for Tough-to-Treat lymphoma

NCT ID NCT05800366

Recruiting now Disease control Sponsor: Jennifer Crombie, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two newer drugs, glofitamab and polatuzumab, to standard chemotherapy (R-CHP) can improve outcomes for people with high-risk diffuse large B-cell lymphoma. About 41 adults with untreated CD20-positive lymphoma will receive the combination. The main goal is to see how many patients achieve complete remission, while also monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA LYMPHOMA, LARGE B-CELL, DIFFUSE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Email: •••••@•••••

Contact
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Email: •••••@•••••

Contact

Contact
University of Miami Sylvester Cancer Center
RECRUITING

Miami, Florida, 33136, United States

Contact